Ascelia Pharma Raises SEK 20 Million in Directed Share Issue Ahead of Orviglance Milestone

Ascelia Pharma AB ( (SE:ACE) ) just unveiled an update.

Ascelia Pharma has completed a directed share issue of 6,666,666 new ordinary shares at SEK 3 per share, raising SEK 20 million from a group of investors including existing shareholders Salenia AB and Mats Thorén. The move, done at roughly a 7 percent discount to the latest closing price, increases the company’s share capital and results in about 5 percent dilution for existing ordinary shareholders.

The proceeds will be used to strengthen Ascelia Pharma’s balance sheet, extend its cash runway into 2027, and support partnering negotiations around its lead imaging drug Orviglance ahead of the FDA’s decision on its New Drug Application in July 2026. The board opted for a directed issue over a rights issue to secure faster, less costly financing, broaden the shareholder base, and limit market risk, and has agreed to short lock-up periods on new share issuance and insider share sales to provide stability around the transaction.

More about Ascelia Pharma AB

Ascelia Pharma AB is a Swedish pharmaceutical company listed on Nasdaq Stockholm that focuses on developing novel oncology-related imaging drugs. Its lead product candidate, Orviglance, is a contrast agent designed for use in liver MRI, and the company is actively pursuing regulatory approval and partnering opportunities, with a key market focus on the U.S. and other major healthcare markets.

Average Trading Volume: 749,986

Technical Sentiment Signal: Hold

Current Market Cap: SEK418M

Learn more about ACE stock on TipRanks’ Stock Analysis page.